GlobeNewswire·Nov 3, 2026, 11:14 AM ET

Rafael Holdings to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference

Rafael Holdings, Inc. will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on November 9, 2026, at 3:55 p.m. ET.
The company will host one-on-one meetings with institutional investors during the event.
A live webcast is available via a provided link, with a replay accessible two hours post-event for up to 30 days.
Rafael Holdings is a biotechnology firm developing pharmaceuticals & holding interests in clinical & early-stage companies creating drugs & medical devices.
The company's lead candidate, remibetadex (Trappsol® Cyclo™), has completed a pivotal Phase 3 study for Niemann-Pick Disease Type C (NPC).
An NDA for remibetadex was submitted to the FDA in October 2026.
NPC is described as a rare, fatal, & progressive genetic disorder.
The company holds interests in other clinical-stage & early-stage pharmaceutical developers & an orthopedic-focused medical device company.
Forward-looking statements warn of risks including the potential failure of the Phase 3 TransportNPC™ study to meet primary endpoints & uncertainty regarding FDA acceptance or approval of the NDA.
Additional risks include the need for financing & substantial doubt about the company's ability to continue as a going concern.
Contact for inquiries is Barbara Ryan at barbara.ryan@rafaelholdings.com or (203) 274-2825.